Trial · NCT06140108
Empagliflozin vs Metformin on Metabolic Dysfunction in Polycystic Ovary Syndrome With or Without Comorbidity or Multimorbidity
NCT06140108, Phase 2, Phase 3, Completed, SINA Health Education and Welfare Trust
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Empagliflozin vs Metformin on Metabolic Dysfunction in Polycystic Ovary Syndrome With or Without Comorbidity or Multimorbidity. Trials, record NCT06140108. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06140108
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Empagliflozin vs Metformin on Metabolic Dysfunction in Polycystic Ovary Syndrome With or Without Comorbidity or Multimorbidity
- NCT number
- NCT06140108
- Status
- Completed
- Phases
- Phase 2, Phase 3
- Enrollment
- 70 participants, actual
- Lead sponsor
- SINA Health Education and Welfare Trust
- Conditions
- Polycystic Ovary Syndrome, Weight Gain, HbA1c
- Interventions
- Empagliflozin 10 MG, MetFORMIN 500 Mg Oral Tablet
- First posted
- 2023-11-18
- Last updated
- 2025-05-14
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Irregular menstruations assessment | Six months treatment with either empagliflozin 10mg or metformin 1000mg daily | Assessment of Irregular menstruation measured by menstruations lasts 2 to 7 days after three months of treatment with either empagliflozin 10mg or metformin 1000mg daily. |
| Secondary | Body weight | Six months treatment with either empagliflozin 10mg or metformin 1000mg daily | assessment of change in Body weight in Kg after three months treatment with either empagliflozin 10mg or metformin 1000mg daily |
| Secondary | Systolic Blood Pressure (SBP) | Six months treatment with either empagliflozin 10mg or metformin 1000mg daily | assessment of change in SBP in mm/Hg after three months treatment with either empagliflozin 10mg or metformin 1000mg daily |
| Secondary | Lipid profile measured through biochemical test | Six months treatment with either empagliflozin 10mg or metformin 1000mg daily | assessment of change in Blood Pressure in mg/dL after three months treatment with either empagliflozin 10mg or metformin 1000mg daily |
| Secondary | Hb1c test | Six months treatment with either empagliflozin 10mg or metformin 1000mg daily | assessment of change in Hb1c level in percentage after three months treatment with either empagliflozin 10mg or metformin 1000mg daily |
| Secondary | fasting blood-glucose measured through biochemical test | Six months treatment with either empagliflozin 10mg or metformin 1000mg daily | assessment of fasting blood-glucose in mmol/L after three months treatment with either empagliflozin 10mg or metformin 1000mg daily |
| Secondary | Diastolic Blood Pressure (DBP) | Six months treatment with either empagliflozin 10mg or metformin 1000mg daily | assessment of change in DBP in mm/Hg after three months treatment with either empagliflozin 10mg or metformin 1000mg daily |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 41257673 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06140108
GET https://conductscience.org/api/trials/v1/NCT06140108/registered